CapsoVision (NASDAQ:CV) Research Coverage Started at Roth Capital

Roth Capital began coverage on shares of CapsoVision (NASDAQ:CV) in a research note published on Friday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $9.00 target price on the stock.

CV has been the topic of several other reports. Benchmark restated a “speculative buy” rating on shares of CapsoVision in a research report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CapsoVision in a report on Monday, June 29th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.50.

CapsoVision Stock Performance

CapsoVision stock opened at $5.93 on Friday. The firm has a 50 day moving average of $6.58 and a 200 day moving average of $6.40. The firm has a market capitalization of $296.80 million and a price-to-earnings ratio of -12.62. CapsoVision has a 12-month low of $3.43 and a 12-month high of $15.37.

CapsoVision (NASDAQ:CV) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share for the quarter. The firm had revenue of $3.64 million for the quarter. CapsoVision had a negative net margin of 214.74% and a negative return on equity of 177.85%.

Insider Buying and Selling

In other CapsoVision news, major shareholder Eliyahou Et Al Harari purchased 81,300 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was acquired at an average cost of $6.09 per share, for a total transaction of $495,117.00. Following the purchase, the insider directly owned 3,282,051 shares of the company’s stock, valued at $19,987,690.59. This trade represents a 2.54% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders purchased 156,218 shares of company stock valued at $1,007,902. 2.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CapsoVision

Hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc purchased a new position in CapsoVision during the second quarter valued at $26,000. Deutsche Bank AG bought a new position in shares of CapsoVision during the 4th quarter valued at about $47,000. Wells Fargo & Company MN boosted its holdings in shares of CapsoVision by 66.4% during the 4th quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after purchasing an additional 2,508 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of CapsoVision during the fourth quarter valued at about $128,000. Finally, Millennium Management LLC purchased a new position in shares of CapsoVision during the fourth quarter valued at about $163,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.